U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07005180) titled 'Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease' on Feb. 28.
Brief Summary: A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).
Study Start Date: Aug. 31
Study Type: INTERVENTIONAL
Condition:
Parkinson Disease
Intervention:
DRUG: HBI-002
Oral liquid containing carbon monoxide
DRUG: Vehicle (placebo)
Vehicle control (placeb...